ANI Pharmaceuticals | ANIP - Gross Profit On Sales


ANI Pharmaceuticals reported $111.79M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
ANI Pharmaceuticals USD 111.79M 1.68M Sep/2025
Assertio Holdings USD 22.24M 970K Jun/2024
Aurora Cannabis CAD 32.29M 4.34M Sep/2025
Canopy Growth CAD 21.9M 3.86M Sep/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Heron Therapeutics USD 23.35M 1.6M Sep/2024
Hikma Pharmaceutical USD 362.5M 329.5M Jun/2025
Knight Therapeutics CAD 44.83M 9.96M Jun/2025
Nektar Therapeutics USD 13.75M 650K Jun/2024
Novartis USD 10.82B 694M Sep/2025
Omeros USD -33.16M 18.52M Jun/2024
Perrigo USD 362.2M 14.9M Dec/2025
Sun Pharmaceuticals INR 107.66B 2.05B Sep/2025
Teva Pharmaceutical Industries USD 2.66B 351M Dec/2025